Prognostic value of baseline FDG PET/CT total metabolic tumor volume and MYC/BCL2 double expression status in patients with diffuse large B-cell lymphoma
Retrospective analysis shows baseline TMTV predicts prognosis in DLBCL patients, highlighting the importance of tumor burden and double expression status.
Key Points
High baseline metabolic tumor volume is a strong independent predictor for overall survival in DE-DLBCL patients.
Among 94 patients, multivariable analysis revealed both TMTV and DE-DLBCL significantly affected progression-free survival at 2 years.
Analysis was based on PET/CT evaluations and prognostic metrics over a median follow-up period of 42 months.
The findings suggest that incorporating TMTV could improve prognostic assessments for lymphoma management.